The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Global disparities in access to novel multiple myeloma therapies
Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, discusses disparities in access to novel therapies for patients with multiple myeloma across Europe and globally. He highlights the relationship between national economic resources and access to effective treatments, emphasizing the substantial challenges faced by patients in lower-income countries. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the issue is access to drugs. And access to drugs is dependent on the gross domestic product of individual countries. So affluent countries with high gross domestic product per capita usually have access or offer access to all drugs or to many drugs. The lower the income per capita, the greater the risk that access to drugs is suboptimal or even not available. We cannot change it from one day to the other...
So the issue is access to drugs. And access to drugs is dependent on the gross domestic product of individual countries. So affluent countries with high gross domestic product per capita usually have access or offer access to all drugs or to many drugs. The lower the income per capita, the greater the risk that access to drugs is suboptimal or even not available. We cannot change it from one day to the other. So we only can help to motivate other societies to be more productive, more competitive. But I don’t see another possibility to increase the access to drugs in poor countries other than allowing them to grow, to expand, to be more commercially profitable, then they will offer their population better access to drugs.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
